StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
KRMD$4.05-0.49%
Fair $4.05+0.0%

KRMD

KORU Medical Systems, Inc.

Healthcare / Medical Instruments & SuppliesNasdaqCM

$4.05

-0.02 (-0.49%)

Fairly Valued+0.0%Fair Value $4.05Fund rank 28/100 · Data gapFallback financials|
SA 32/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-1.7M · quality 56.7/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 24/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

32/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 15Warnings: 1unknown: 15
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -15.5%, below the 5% threshold
Thesis & Journal · KRMDLocal privado en este navegador · KORU Medical Systems, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$186M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-15.5%

↓

Gross Margin

62.3%

↑

Debt/Equity

0.21

↓
52-Week Range$4
$3$7

TradingView lightweight chart

KRMD price, volumen y niveles de valoración

Último $4.050Periodo +2214.3%
Fair value: $4.050

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2011–2025 · 14 años de histórico normalizado

Revenue CAGR

+16.4%

FCF CAGR

—

FCF margin

-1.2%

FCF / Net income

0.19x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $41.1M · net income $-2.6M · FCF $-494085.0

2011-FY → 2025-FY

Gross margin

62.3%— pts

Operating margin

-7.2%-31.5% pts

Net margin

-6.4%-20.7% pts

FCF margin

-1.2%-18.0% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Income Statement
Revenue$41.1M$41.1M$33.6M$28.5M$27.9M$23.5M$24.2M$23.2M$17.4M—$12.2M$11.2M$8.7M$7.8M$6.4M$4.9M
Net Income$-2.6M$-2.6M$-6.1M$-13.7M$-8.7M$-4.6M$-1.2M$564349.00$910570.00$904957.00$782864.00$753117.00$703429.00$725763.00$815893.00$704085.00
EBITDA$-2.2M$-2.2M$-5.6M$-9.4M$-10.2M$-6.6M$-836190.00$925908.00$1.5M$1.5M$1.5M$1.4M$1.2M$1.3M$1.4M$1.3M
EPS-0.06-0.06-0.13-0.30-0.19-0.10-0.030.010.020.020.020.020.020.020.020.02
Gross Margin62.3%62.3%63.4%58.6%55.1%58.6%61.8%64.1%62.3%—62.1%59.5%61.0%———
Operating Margin-7.2%-7.2%-19.2%-36.0%-38.6%-29.9%-5.2%2.5%6.7%—9.6%10.2%11.6%13.7%20.2%24.3%
Net Margin-6.4%-6.4%-18.0%-48.2%-31.0%-19.4%-5.0%2.4%5.2%—6.4%6.7%8.1%9.3%12.8%14.3%
Balance Sheet
Debt/Equity0.210.210.240.220.16————————0.090.12—
Current Ratio2.332.33——————————————
Cash Flow
Free Cash Flow$-494085.00$-494085.00$-1.7M$-5.7M$-8.2M——————$234686.00$765702.00$221223.00$324366.00$827943.00
Returns
ROE-15.5%-15.5%-36.1%-67.5%-27.6%-12.5%-3.4%5.0%10.2%11.8%11.0%12.0%13.5%16.7%23.0%28.4%
Valuation
P/B10.9710.9710.624.955.49———————————
Growth & Yield
Revenue Growth22.2%22.2%18.0%2.2%—-2.8%4.4%33.5%——8.9%29.3%12.0%21.5%29.9%—
EPS Growth53.8%53.8%56.7%-57.9%—-233.3%-400.0%-50.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +45.2%

Total return

+45.2%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.13 → -0.06

Residual

+45.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+45.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.